Amgen shares fell 5.4% in the premarket; late-stage clinical trials of rival Novartis cholesterol drugs failed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.